“It’s difficult to make predictions – especially about the future.” – Yogi Berra
A decade ago, Dr. Aaron Miller, Mount Sinai, New York, took a game swing at the crystal ball and wrote the article, “Multiple sclerosis: where will we be in 2020?” (Miller A. Mt Sinai J Med 2011;78:268-279). Read More
The Institute for Clinical and Economic Review (ICER), a drug pricing watchdog in the U.S., has ruled that novel oral migraine therapies have similar effectiveness but are not superior to triptans (5-HT 1B/1D agonists). Read More
A new study reports that hematologic abnormalities may occur in one-third of infants exposed to natalizumab during the third trimester but treatment was generally safe (Triplett et al. Mult Scler Relat Disord 2020;40:101961). Read More
A number of new drugs for neurology and psychiatry are currently in review with regulatory authorities in the U.S. and Canada. The following summarizes some of the key therapies expected to be approved in 2020. Read More